Experimental evidence in cancer immunotherapy shows that inhibition of acetyl-CoA acetyltransferase-1 (ACAT1), an enzyme that increases intracellular esterified cholesterol levels, improves the efficacy of anti–PD-1 therapy in melanoma (158). Here, ACAT1 is linked to cancer.